دورية أكاديمية
أعرض في EDS

Defining and targeting macrophage heterogeneity in the mammary gland and breast cancer.

التفاصيل البيبلوغرافية
العنوان: Defining and targeting macrophage heterogeneity in the mammary gland and breast cancer.
المؤلفون: Elfstrum AK; Microbiology, Immunology, and Cancer Biology Graduate Program, University of Minnesota, Minneapolis, Minnesota, USA., Bapat AS; Molecular Pharmacology and Therapeutics Graduate Program, University of Minnesota, Minneapolis, Minnesota, USA., Schwertfeger KL; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA.; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA.; Center for Immunology, University of Minnesota, Minneapolis, Minnesota, USA.
المصدر: Cancer medicine [Cancer Med] 2024 Feb; Vol. 13 (3), pp. e7053.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Malden, MA] : John Wiley & Sons Ltd., c2012-
مواضيع طبية MeSH: Mammary Glands, Human*/pathology , Breast Neoplasms*/pathology, Animals ; Humans ; Female ; Mammary Glands, Animal/pathology ; Breast/pathology ; Macrophages
مستخلص: Introduction: Macrophages are innate immune cells that are associated with extensive phenotypic and functional plasticity and contribute to normal development, tissue homeostasis, and diseases such as cancer. In this review, we discuss the heterogeneity of tissue resident macrophages in the normal mammary gland and tumor-associated macrophages in breast cancer. Tissue resident macrophages are required for mammary gland development, where they have been implicated in promoting extracellular matrix remodeling, apoptotic clearance, and cellular crosstalk. In the context of cancer, tumor-associated macrophages are key drivers of growth and metastasis via their ability to promote matrix remodeling, angiogenesis, lymphangiogenesis, and immunosuppression.
Method: We identified and summarized studies in Pubmed that describe the phenotypic and functional heterogeneity of macrophages and the implications of targeting individual subsets, specifically in the context of mammary gland development and breast cancer. We also identified and summarized recent studies using single-cell RNA sequencing to identify and describe macrophage subsets in human breast cancer samples.
Results: Advances in single-cell RNA sequencing technologies have yielded nuances in macrophage heterogeneity, with numerous macrophage subsets identified in both the normal mammary gland and breast cancer tissue. Macrophage subsets contribute to mammary gland development and breast cancer progression in differing ways, and emerging studies highlight a role for spatial localization in modulating their phenotype and function.
Conclusion: Understanding macrophage heterogeneity and the unique functions of each subset in both normal mammary gland development and breast cancer progression may lead to more promising targets for the treatment of breast cancer.
(© 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
References: Breast Cancer Res. 2006;8(1):201. (PMID: 16524451)
Immunity. 2016 Mar 15;44(3):439-449. (PMID: 26982352)
J Biomed Sci. 2019 Oct 20;26(1):78. (PMID: 31629410)
Cell Rep. 2021 Oct 19;37(3):109844. (PMID: 34686340)
Nat Immunol. 2014 Nov;15(11):1026-37. (PMID: 25263125)
Nat Cancer. 2023 Apr;4(4):516-534. (PMID: 36927792)
Front Immunol. 2018 Feb 01;9:93. (PMID: 29449841)
Immunity. 2015 Aug 18;43(2):382-93. (PMID: 26287683)
Cell Res. 2015 Oct;25(10):1121-36. (PMID: 26358190)
Cancer Res. 2009 Mar 1;69(5):2000-9. (PMID: 19244125)
Mediators Inflamm. 2017;2017:9624760. (PMID: 28210073)
Cancer Cell. 2011 Apr 12;19(4):512-26. (PMID: 21481792)
Sci Immunol. 2022 Jan 07;7(67):eabf7777. (PMID: 34995099)
Immunity. 2013 Apr 18;38(4):792-804. (PMID: 23601688)
Oncotarget. 2015 Mar 30;6(9):7221-31. (PMID: 25749047)
Front Immunol. 2015 Sep 22;6:486. (PMID: 26441990)
Sci Adv. 2021 Nov 05;7(45):eabg9518. (PMID: 34730997)
Nat Immunol. 2014 Oct;15(10):929-937. (PMID: 25151491)
J Exp Med. 2001 Mar 19;193(6):727-40. (PMID: 11257139)
Mol Neurodegener. 2015 Sep 04;10:43. (PMID: 26337043)
J Exp Med. 2005 Feb 21;201(4):647-57. (PMID: 15728241)
Nat Immunol. 2013 Oct;14(10):986-95. (PMID: 24048120)
Cancer Immunol Res. 2022 Nov 2;10(11):1340-1353. (PMID: 36122412)
Cell. 2010 Apr 2;141(1):39-51. (PMID: 20371344)
Oncoimmunology. 2022 Jun 8;11(1):2085432. (PMID: 35712121)
Science. 1994 Apr 29;264(5159):713-6. (PMID: 8171324)
Immunol Lett. 2009 Apr 27;123(2):97-102. (PMID: 19428556)
J Mammary Gland Biol Neoplasia. 2023 Jan 27;28(1):1. (PMID: 36723776)
Cell. 2014 Dec 4;159(6):1327-40. (PMID: 25480297)
J Mammary Gland Biol Neoplasia. 2020 Jun;25(2):103-113. (PMID: 32535810)
Nature. 2023 Aug;620(7972):181-191. (PMID: 37380767)
Immunity. 2013 Jan 24;38(1):79-91. (PMID: 23273845)
Arch Pharm Res. 2019 Aug;42(8):658-671. (PMID: 31243646)
Curr Opin Lipidol. 2022 Oct 1;33(5):283-288. (PMID: 35942822)
Front Physiol. 2018 May 01;9:419. (PMID: 29765329)
Cell. 2021 Feb 4;184(3):792-809.e23. (PMID: 33545035)
Dev Cell. 2023 Sep 11;58(17):1548-1561.e10. (PMID: 37442140)
Immunity. 2014 Jul 17;41(1):21-35. (PMID: 25035951)
Proc Natl Acad Sci U S A. 2019 Jun 18;116(25):12442-12451. (PMID: 31147469)
J Pathol. 2006 May;209(1):67-77. (PMID: 16482496)
Nat Commun. 2019 Jan 17;10(1):281. (PMID: 30655530)
Cancer Res. 2006 May 15;66(10):5242-50. (PMID: 16707449)
Wiley Interdiscip Rev Dev Biol. 2012 Jul-Aug;1(4):533-57. (PMID: 22844349)
Dev Dyn. 2006 Dec;235(12):3222-9. (PMID: 17029292)
Trends Immunol. 2022 Jul;43(7):546-563. (PMID: 35690521)
Cell. 2018 Aug 23;174(5):1293-1308.e36. (PMID: 29961579)
J Exp Clin Cancer Res. 2022 Feb 19;41(1):68. (PMID: 35183252)
Cell. 2022 Mar 31;185(7):1189-1207.e25. (PMID: 35325594)
Clin Cancer Res. 2012 Mar 1;18(5):1207-13. (PMID: 22205687)
Oncol Rep. 2019 Dec;42(6):2499-2511. (PMID: 31578575)
Cancer Cell. 2015 Apr 13;27(4):462-72. (PMID: 25858805)
J Enzymol Metab. 2015;1(1):. (PMID: 26937490)
Breast Cancer Res. 2002;4(4):155-64. (PMID: 12100741)
Cancer Discov. 2016 Mar;6(3):270-85. (PMID: 26715645)
Front Cell Neurosci. 2021 Oct 13;15:722028. (PMID: 34720877)
Nature. 2000 Aug 17;406(6797):747-52. (PMID: 10963602)
Clin Cancer Res. 2020 Jun 1;26(11):2640-2653. (PMID: 32060101)
Cancer Res. 2018 Nov 15;78(22):6473-6485. (PMID: 30254150)
Mol Neurodegener. 2017 Aug 2;12(1):56. (PMID: 28768545)
Cancer Sci. 2017 Aug;108(8):1693-1700. (PMID: 28574667)
Immunobiology. 2006;211(6-8):407-17. (PMID: 16920480)
Int J Mol Sci. 2021 May 25;22(11):. (PMID: 34070369)
Breast Cancer Res. 2021 Nov 7;23(1):104. (PMID: 34743736)
J Clin Pathol. 2012 Feb;65(2):159-63. (PMID: 22049225)
Semin Cell Dev Biol. 2017 Jan;61:3-11. (PMID: 27521521)
Curr Oncol Rep. 2017 Sep 5;19(11):70. (PMID: 28875266)
Curr Opin Immunol. 2006 Feb;18(1):39-48. (PMID: 16337366)
Cancer Sci. 2018 Oct;109(10):3171-3182. (PMID: 30058195)
Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5592-6. (PMID: 8202532)
Breast Cancer Res. 2023 Aug 29;25(1):100. (PMID: 37644609)
Hypoxia (Auckl). 2014 Mar 31;2:23-33. (PMID: 27774464)
Front Oncol. 2020 Sep 24;10:569985. (PMID: 33072601)
Cancer Discov. 2011 Jun;1(1):54-67. (PMID: 22039576)
J Exp Med. 1999 Jul 19;190(2):293-8. (PMID: 10432291)
Front Immunol. 2021 Sep 30;12:734229. (PMID: 34659222)
Nat Biotechnol. 2020 Aug;38(8):947-953. (PMID: 32361713)
J Immunol. 2008 Aug 1;181(3):2220-6. (PMID: 18641362)
EMBO J. 2021 Jun 1;40(11):e107333. (PMID: 33950524)
Cancer Res. 2021 Oct 15;81(20):5284-5295. (PMID: 34389631)
Cancer Gene Ther. 2022 Jan;29(1):10-21. (PMID: 33603130)
Organogenesis. 2013 Oct 1;9(4):249-60. (PMID: 23974218)
J Mammary Gland Biol Neoplasia. 2010 Sep;15(3):329-39. (PMID: 20730636)
Cancer Cell. 2011 Apr 12;19(4):541-55. (PMID: 21481794)
Nat Commun. 2018 Jan 2;9(1):21. (PMID: 29295986)
Arthritis Rheum. 1999 Aug;42(8):1609-16. (PMID: 10446858)
Cell. 2022 Nov 10;185(23):4259-4279. (PMID: 36368305)
J Biol Chem. 2009 Oct 16;284(42):29087-96. (PMID: 19720836)
Genes Dev. 2011 Dec 1;25(23):2465-79. (PMID: 22156207)
Nature. 2014 Nov 6;515(7525):130-3. (PMID: 25337873)
Int J Clin Exp Pathol. 2013;6(4):561-70. (PMID: 23573303)
Mol Clin Oncol. 2017 Oct;7(4):515-520. (PMID: 28855985)
Eur J Immunol. 2021 Aug;51(8):1882-1896. (PMID: 34107057)
Immunity. 2015 Dec 15;43(6):1023-4. (PMID: 26682973)
Nat Commun. 2017 May 05;8:15081. (PMID: 28474673)
J Cell Mol Med. 2006 Jul-Sep;10(3):635-49. (PMID: 16989725)
Immunology. 2022 Feb;165(2):206-218. (PMID: 34775606)
Clin Cancer Res. 2000 Aug;6(8):3282-9. (PMID: 10955814)
Front Cell Dev Biol. 2019 Oct 24;7:250. (PMID: 31709255)
J Mammary Gland Biol Neoplasia. 2006 Oct;11(3-4):229-38. (PMID: 17115264)
Anticancer Agents Med Chem. 2021 Dec 30;22(2):294-312. (PMID: 34145996)
Cancer Treat Rev. 2018 Nov;70:178-189. (PMID: 30227299)
Cancer Res. 2006 Dec 1;66(23):11238-46. (PMID: 17114237)
Cancer Sci. 2020 Nov;111(11):4000-4011. (PMID: 32798273)
Cell. 2014 Dec 4;159(6):1312-26. (PMID: 25480296)
Development. 2020 Jun 17;147(12):. (PMID: 32467242)
Dev Biol. 2017 Aug 1;428(1):232-244. (PMID: 28606561)
J Mammary Gland Biol Neoplasia. 2014 Jul;19(2):191-201. (PMID: 24924120)
Cell. 2020 Aug 20;182(4):872-885.e19. (PMID: 32783915)
Breast Cancer Res Treat. 2016 Jul;158(1):113-126. (PMID: 27283835)
Cancer Sci. 2023 Jun;114(6):2220-2229. (PMID: 36748310)
Cancer Res. 2022 Sep 16;82(18):3291-3306. (PMID: 35862581)
Development. 2012 Jan;139(2):269-75. (PMID: 22129827)
Sci Rep. 2022 Jul 14;12(1):12007. (PMID: 35835809)
Adv Drug Deliv Rev. 2004 Apr 29;56(8):1067-84. (PMID: 15094207)
Thorac Cancer. 2022 Feb;13(3):269-276. (PMID: 34914196)
Cancer Res. 2011 Oct 1;71(19):6143-52. (PMID: 21852386)
Nat Genet. 2021 Sep;53(9):1334-1347. (PMID: 34493872)
Development. 2000 Jun;127(11):2269-82. (PMID: 10804170)
Annu Rev Med. 2010;61:105-19. (PMID: 19824815)
Cell. 2020 Apr 16;181(2):442-459.e29. (PMID: 32302573)
Oncotarget. 2015 Oct 6;6(30):29637-50. (PMID: 26359357)
J Ovarian Res. 2015 May 14;8:29. (PMID: 25971554)
Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9312-6. (PMID: 7937762)
World J Clin Oncol. 2014 Aug 10;5(3):412-24. (PMID: 25114856)
Oncotarget. 2016 May 24;7(21):31097-110. (PMID: 27105498)
Cancers (Basel). 2021 Apr 18;13(8):. (PMID: 33919517)
Nat Immunol. 2009 Sep;10(9):943-8. (PMID: 19692995)
Breast Cancer Res Treat. 2022 Oct;195(3):237-248. (PMID: 35917053)
Proc Natl Acad Sci U S A. 2022 Apr 26;119(17):e2107394119. (PMID: 35439048)
Breast Cancer Res Treat. 2011 Aug;128(3):703-711. (PMID: 20842526)
Onco Targets Ther. 2014 Aug 21;7:1475-80. (PMID: 25187727)
J Leukoc Biol. 2019 Aug;106(2):259-274. (PMID: 30720887)
Front Oncol. 2021 Feb 24;11:620773. (PMID: 33718177)
Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12425-30. (PMID: 21746895)
Front Immunol. 2021 Apr 23;12:643771. (PMID: 33968034)
J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):177-89. (PMID: 12463738)
Ann Surg Oncol. 2012 Nov;19(12):3979-86. (PMID: 22622474)
Trends Immunol. 2019 Apr;40(4):310-327. (PMID: 30890304)
Results Probl Cell Differ. 2017;62:353-364. (PMID: 28455716)
Cancer Res. 2020 Oct 15;80(20):4465-4475. (PMID: 32868380)
Nat Cell Biol. 2020 May;22(5):546-558. (PMID: 32341550)
Cell Metab. 2019 Nov 5;30(5):917-936.e10. (PMID: 31447322)
Breast Cancer Res Treat. 2018 Aug;170(3):477-486. (PMID: 29594759)
BMC Cancer. 2012 Jul 23;12:306. (PMID: 22824040)
J Immunol. 2019 Jan 1;202(1):48-55. (PMID: 30518570)
Immunity. 2014 Jul 17;41(1):49-61. (PMID: 25035953)
J Surg Res. 2018 Feb;222:93-101. (PMID: 29273380)
Elife. 2020 Jun 01;9:. (PMID: 32479261)
Cold Spring Harb Perspect Biol. 2010 Aug;2(8):a003186. (PMID: 20554705)
Cancers (Basel). 2022 Nov 09;14(22):. (PMID: 36428599)
Science. 2019 Mar 15;363(6432):. (PMID: 30872492)
Nat Rev Cancer. 2004 Jan;4(1):71-8. (PMID: 14708027)
Cell. 2020 Aug 20;182(4):886-900.e17. (PMID: 32783918)
Cancer Res. 2004 Oct 1;64(19):7022-9. (PMID: 15466195)
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2796-801. (PMID: 21825174)
Cell. 2019 Jul 25;178(3):686-698.e14. (PMID: 31257031)
Immunity. 2021 Aug 10;54(8):1883-1900.e5. (PMID: 34331874)
Sci Rep. 2018 Jan 10;8(1):256. (PMID: 29321503)
Development. 2010 Dec;137(24):4229-38. (PMID: 21068060)
J Exp Med. 2017 Mar 6;214(3):597-607. (PMID: 28209725)
J Cell Sci. 2009 Sep 15;122(Pt 18):3365-73. (PMID: 19726632)
Cell. 2014 May 8;157(4):832-44. (PMID: 24792964)
Nat Rev Drug Discov. 2022 Nov;21(11):799-820. (PMID: 35974096)
Oncogene. 2017 Oct 26;36(43):6049-6058. (PMID: 28759044)
J Exp Clin Cancer Res. 2018 Dec 11;37(1):307. (PMID: 30537992)
Nat Immunol. 2023 Jul;24(7):1098-1109. (PMID: 37337103)
Sci Rep. 2021 Sep 9;11(1):18007. (PMID: 34504204)
Cell Mol Immunol. 2020 Jan;17(1):95-107. (PMID: 30842629)
Arthritis Rheum. 2007 Mar;56(3):1010-20. (PMID: 17328080)
Sci Signal. 2010 May 18;3(122):ra38. (PMID: 20484116)
Circ Res. 2018 Oct 26;123(10):1127-1142. (PMID: 30359200)
Semin Cell Dev Biol. 2014 Apr;28:49-56. (PMID: 24631357)
PLoS One. 2015 Apr 17;10(4):e0125728. (PMID: 25884955)
معلومات مُعتمدة: R01CA215052 United States CA NCI NIH HHS; R01 CA265004 United States CA NCI NIH HHS; R01 HD106929 United States HD NICHD NIH HHS; R01 HD095858 United States HD NICHD NIH HHS; R01CA265004 United States CA NCI NIH HHS; R01 CA215052 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: LYVE-1; TREM2; breast cancer; macrophage; mammary gland
تواريخ الأحداث: Date Created: 20240301 Date Completed: 20240304 Latest Revision: 20240320
رمز التحديث: 20240320
مُعرف محوري في PubMed: PMC10905685
DOI: 10.1002/cam4.7053
PMID: 38426622
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-7634
DOI:10.1002/cam4.7053